
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group is transitioning due to changes in Medicare reimbursement and facing slower market recovery due to pricing and payment process confusion. The success of their products is dependent on tissue donorship, procurement scalability, and competition in the evolving skin substitute landscape. Revenue risk is present as 76% of 2024 revenue is from membership in primary GPOs or IDNs; a 20% base salary reduction from the CEO and heightened cost control measures highlight MDXG's commitment to growth initiatives despite this, and management will elaborate on how such initiatives and restructuring intend to drive higher growth in their Q2'26 conference call.
Bears say
MiMedx Group is currently facing multiple challenges that are negatively impacting its financial performance and outlook. These include the negative impact of recent CMS reimbursement changes, a decline in sales due to disruptions caused by the COVID-19 pandemic, and a reduction in workforce to cut costs. While the company has a strong portfolio of products and a vertically integrated manufacturing infrastructure, it may still take some time for demand to return to normal levels. Additionally, the company's recent restructuring efforts are expected to result in annual savings of $40 million, but this may not be enough to offset the current challenges it is facing.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares